个人简介

张辉教授是中组部海外高层次人才计划入选者（2009创新第二批, 全职在中山大学工作），国家特聘专家。中山大学中山医学院“国华”讲习教授，中山大学人类病毒学研究所所长。本科毕业于中山医学院临床医学专业，当过三年内科住院医师，在中山医科大学中山三院血液内科获得医学硕士学位，在美国纽约州立大学上州医学中心获理学博士学位。1997年被聘为费城托马斯-杰佛逊大学医学院传染内科并人类病毒学研究中心助理教授， 2008 年升为正教授（终身）。 2005 年起被任命为杰佛逊大学人类病毒学和生物防护研究所副所长。作为项目主持人(PI), 曾经获得 4 项美国NIH RO1 基金支持，并在 1 项助理教授的 NIH KO1 基金中任导师 (Mentor)。自2012年12月起，完全关闭美国的实验室，全职在中山大学任教，创建中山大学人类病毒学研究所。回国后带领人类病毒学研究团队作为第一名入选首批广东省“珠江人才计划”引进创新团队，结题验收为优秀。

张辉教授作为第一作者，发表论文在《NEJM》、《PNAS》、《J. Virol》等杂志上；作为主要通讯作者， 发表论文在《Nature》、《Nature Med》、《Nat. Immunol》、《Immunity》、《JCI》、《PNAS》、《EMBO J》、《Nature Comm》、《NAR》、《Advanced Science》、《STTT》、《CMI》、《Mol Therapy》、《Cell Reports》、《eLife》、《mBio》、《Plos Path》、《J. Virol》等杂志上。发表 SCI 论文 150 篇以上，论文总引次数在 12000以上。回国后的科研成果已经申请100多项国内和国际专利，已获授权超过60项。近几年作为项目负责人先后主持国家艾滋病和病毒性肝炎等传染病防治重大专项“十二五”及“十三五”各一项（已结题）、一项国家自然基金委重大项目（已结题）、一项国际合作（中国 NSFC-美国 NIH）项目（已结题）、一项国家自然基金委重点项目（已结题）、两项国家自然基金委重大研究计划项目（在研）、一项国家自然基金委新冠特别项目（已结题）。是研究生教材《分子病毒学》（人卫版）副主编。长期参与中山医学院医学生五年制和八年制《医学微生物学》课堂教学，以及作为课程负责人，主持研究生和本科生《生物医学论文导读》的讨论课教学。

学术成果

回国前代表性工作

1    Zhang H, Dornadula G, Beumont M, Livornese L Jr, Van Uitert B, Henning K, Pomerantz RJ. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. New England Journal of Medicine. 1998. 339: 1803-1839

2     Zhang H*, Pomerantz RJ, Dornadula G, Sun Y. Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process. Journal of Virology. 2000. 74: 8252-8261.

3     Dornadula G, Yang SC, Pomerantz RJ, Zhang H*. Partial rescue of the Vif-negative phenotype of mutant HIV-1 viruses from non-permissive cells by intravirion reverse transcription. Journal of Virology. 2000. 74: 2594-2602.

4     Zhang H*, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L. The cytidine deaminase CEM15 induces hypermutation in newly-synthesized HIV-1 DNA. Nature. 2003. 424: 94-98.

5     Chen K, Huang J, Zhang C, Huang S, Nunnari G, Wang FX, Tong X, Gao, L, Nikisher K, Zhang H*. Alpha interferon potently enhances the anti-HIV-1 activity of APOBEC3G in resting primary CD4 T-cells. Journal of Virology. 2006. 80: 7645-7657

6     Huang JL, Wang FX, Argyris E, Chen KY, Liang ZH, Tian H, Huang WL, Squires K, Verlinghieri G, and Zhang H*: Cellular microRNAs contribute to HIV-1 latency in resting CD4+ T-lymphocytes. Nature Medicine. 2007. 13: 1241-1247

最近五年代表性工作

1．Ma XC, Yang T, Luo YW, Wu LY, Jiang YW, Song Z, Pan T, Liu BF, Liu G, Liu J, Yu F, He Z, Zhang W, Yang J, Liang L, Guan Y, Zhang X, Li L, Cai W, Tang X, Gao S, Deng K, and Zhang H*. TRIM28 promotes HIV-1 latency by SUMOylating CDK9 and inhibiting P-TEFb. eLife. 2019. 8: e42426.

2．Pan T, Song Z, Wu L, Liu G, Ma X, Peng Z, Zhou M, Liang L, Liu B, Liu J, Zhang J, Zhang X, Huang R, Zhao J, Li Y, Ling X, Luo Y, Tang X, Cai W, Deng K, Li L*, and Zhang H*. USP49 potently stabilizes APOBEC3G protein by removing ubiquitin and inhibits HIV-1 replication. eLife. 2019. 8: e48318.

3.    Luo YW, Liu Y, Wu LY, Ma XC, Liu Q, Huang F, Zhang X, Zhang YW, Zhang JS, Luo HH， Yang Y, Lu G, Tang XP, Li LH, Zeng YX, Pan T*, and Zhang H*. CUL7 E3 Ubiquitin Ligase Mediates the Degradation of Activation-induced Cytidine Deaminase (AID) and Regulates the Immunoglobulin Class Switch Recombination in B-Lymphocytes. Journal of Immunology. 2019. 203: 269-281.

4    Zou F, Lu LJ, Liu J, Xia BJ, Zhang WY, Hu QF, Liu WW, Zhang YW, Lin YT, Jing SL, Huang M, Huang BF, Liu BF*, and Zhang H*. Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56. Nature Communications. 2019. 10(1): 4109.

5     Yu F, Li Q, Chen X, Liu J, Li L, Li B, Liu B, Zhang J, Zhang X, Liu Z, Luo H, Tang XP, Cai W, Zhang H*, and Deng K*. X4-Tropic Latent HIV-1 Is Enriched in Peripheral Follicular Helper T Cells and Is Correlated with Disease Progression. Journal of Virology. 2020. 94(2): e01219-19.

6     Zhang JS, Liu J, Yuan YC, Huang F, Ma R, Luo BH, Xi ZH, Pan T, Liu BF, Zhang YW, Zhang X, Luo YW, Wang J, Zhao M, Lu G, Deng K*, and Zhang H*. Two waves of pro-inflammatory factors are released during the influenza A virus (IAV)-driven pulmonary immunopathogenesis. PLoS Pathogens. 2020. 16(2): e1008334.

7     He ZP, Jing SL, Yang T, Chen JL, Huang F, Zhang WY, Peng ZL, Liu BF, Ma XC, Wu LY, Pan T, Zhang X, Li LH, Cai WP, Tang XP, Zhang JS*, and Zhang H*. PIWIL4 maintains HIV-1 latency by enforcing epigenetically suppressive modifications on the 5' long terminal repeat. Journal of Virology. 2020. 94(10): e01923-19.

8     Zhang YW, Chen YS, Ma R, Jiang YW, Liu J, Lin YT, Chen SQ, Xia MY, Zou F, Zhang JS, Pan T, Wang L, Wei L*, and Zhang H*. UHRF1 Controls Thymocyte Fate Decisions through the Epigenetic Regulation of EGR1 Expression. Journal of Immunology. 2020. 204(12): 3248-3261.

9     Liu BF, Shi YL, Zhang WY, Li R, He ZP, Yang XF, Pan YJ, Deng XL, Tan MK, Zhao LZ, Zou F, Zhang YW, Pan T, Zhang JS, Zhang X, Xiao F, Li F*, Deng K*, and Zhang H*. Recovered COVID-19 patients with recurrent viral RNA exhibit lower levels of anti-RBD antibodies. Cellular and Molecular Immunology. 2020.17(10): 1098-1100.

10   Luo BH, Zhan YK, Luo MQ, Dong HM, Liu J, Lin YT, Zhang JS, Wang GW, Zhang YW *, and Zhang H*. Engineering of α-PD-1 Antibody-Expressing Long-lived Plasma Cells by CRISPR/Cas9-Mediated Targeted Gene Integration. Cell Death and Diseases. 2020.11(11): 973.

11   Ma XC, Zou F, Yu F, Li R, Yuan YC, Zhang YW, Zhang XT, Deng JY, Chen T, Song Z, Qiao YD, Zhan YK, Liu J, Zhang JS, Zhang X, Peng ZL, Li YZ, Lin YT, Liang LT, Wang GW, Chen YS, Chen QE, Pan T, He X, and Zhang H *. Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses. Immunity. 2020. 53(6): 1315-1330.

12   Luo YW, Yu F, Zhou M, Liu Y, Xia BJ, Zhang XT, Liu J, Zhang JS, Du YY, Li R, Wu LY, Zhang X, Pan T, Guo DY, Peng T, and Zhang H*. Engineering a Reliable and Convenient SARS-CoV-2 Replicon System for Analysis of Viral RNA Synthesis and Screening of Antiviral Inhibitors. mBio. 2021.12: e02754-20.

13   Ma X, Chen T, Peng Z, Wang Z, Liu J, Yang T, Wu L, Liu G, Zhou M, Tong M, Guan Y, Zhang X, Lin Y, Tang X, Li L, Tang Z, Pan T, and Zhang H*. Histone chaperone CAF-1 promotes HIV-1 latency by leading the formation of phase-separated suppressive nuclear bodies. EMBO Journal. 2021. 40(10): e106632.

14   Li R, Ma XC, Deng JY, Chen QE, Liu WW, Peng ZL, Qiao YD, Lin YT, He X*, and Zhang H*. Differential efficiencies to neutralize the novel mutants B.1.1.7 and 501Y.V2 by collected sera from convalescent COVID-19 patients and RBD nanoparticle-vaccinated rhesus macaques. Cellular and Molecular Immunology. 2021. 18:1058-1060.

15   Zou F, Tan J, Liu T, Liu B, Tang Y, Zhang H*, and Li J*. The CD39+ HBV surface protein-targeted CAR-T and personalized tumor-reactive CD8+ T cells exhibit potent anti-HCC activity. Molecular Therapy. 2021. 29(5): 1794-1807.

16   Zhang YW, Hu H, Liu W, Yan SM, Li Y, Tan L, Chen Y, Liu J, Peng Z, Yuan Y, Huang W, Yu F, He X, Li B*, and Zhang H*. Amino acids and RagD potentiate mTORC1 activation in CD8+ T cells to confer antitumor immunity. Journal of Immunotherapy of Cancer. 2021. 9(4): e002137.

17   Zhang JS, Huang F, Xia BJ, Yuan YC, Yu F, Wang GW, Chen QY, Wang Q, Li YZ, Li R, Song Z, Pan T, Chen JL, Lu G, and Zhang H*. The interferon-stimulated exosomal hACE2 potently inhibits SARS-CoV-2 replication through competitively blocking the virus entry. Signal Transduction and Targeted Therapy. 2021. 6(1): 189.

18   Zhang YW, Chen YS, Li YZ, Huang F, Luo BH, Yuan YC, Xia BJ, Ma XC, Yang T, Yu F, Liu J, Liu BF, Song Z, Chen JL, Yan SM, Wu LY, Pan T, Zhang X, Li R, Huang WJ, He X, Xiao F, Zhang JS*, and Zhang H*. The ORF8 Protein of SARS-CoV-2 Mediates Immune Evasion through Downregulating MHC-Ι. Proceedings of the National Academy of Sciences (USA). 2021. 118(23): e2024202118.

19   Zhang X, Yuan Y, Wu B, Wang X, Lin Y, Luo Y, Li R, Chen T, Deng J, Zhang X, Zou F, He X*, Zhang H*. Improvement of a SARS-CoV-2 vaccine by enhancing the conjugation efficiency of the immunogen to self-assembled nanoparticles. Cellular and Molecular Immunology. 2021. 18(8):2042-2044.

20   Pan T, Hu Z, Hu F, Zhang Y, Liu B, Ke C, She Q, He X*, Tang X*, Zhang H*. Significantly reduced abilities to cross-neutralize SARS-CoV-2 variants by sera from convalescent COVID-19 patients infected by Delta or early strains. Cellular and Molecular Immunology. 2021. 18(11):2560-2562.

21   Liu B, Zhang W, Xia B, Jing S, Du Y, Zou F, Li R, Lu L, Chen S, Li Y, Hu Q, Lin Y, Zhang Y, He Z, Zhang X, Chen X, Peng T, Tang X, Cai W, Pan T*, Li L*, Zhang H*. Broadly neutralizing antibody-derived CAR T cells reduce viral reservoir in individuals infected with HIV-1. Journal of Clinical Investigation. 2021.131(19):e150211.

22   Pan T, Chen R, He X, Yuan Y, Deng X, Li R, Yan H, Yan S, Liu J, Zhang Y, Zhang X, Yu F, Zhou M, Ke C, Ma X*, Zhang H*. Infection of wild-type mice by SARS-CoV-2 B.1.351 variant indicates a possible novel cross-species transmission route. Signal Transduction and Targeted Therapy. 2021. 6(1): 420.

23   Zhang X, Wu S, Wu B, Yang Q, Chen A, Li Y, Zhang Y, Pan T, Zhang* H, He X*. SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance. Signal Transduction and Targeted Therapy. 2021. 6(1):430.

24   Yuan Y, Zhang X, Chen R, Li Y, Wu B, Li R, Zou F, Ma X, Wang X, Chen Q, Deng J, Zhang Y, Chen T, Lin Y, Yan S, Zhang X, Li C, Bu X, Peng Y, Ke C, Deng K, Pan T, He X, Zhang Y*, Zhang H*. A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2. Cell Reports. 2022. 38(3):110256.

25   Luo Y, Zhang X, Chen R, Li R, Liu Y, Zhang J, Liu Q, Si M, Liu J, Wu B, Wang X, Wu S, Zhang Y, Zhang X, Guo D, He X, Pan T, Zhang H*. USP10 regulates B cell response to SARS-CoV-2 or HIV-1 nanoparticle vaccines through deubiquitinating AID. Signal Transduction and Targeted Therapy. 2022. 7(1):7.

26    Chen R ,  Zhang XT , Yuan YC , Deng  XH ............. Zhang H*. Development of Receptor Binding Domain (RBD)-Conjugated Nanoparticle Vaccines with Broad Neutralization against SARS-CoV-2 Delta and Other Variants. Adv Sci (Weinh). 2022 Apr;9(11).

27   Zhang  XT , Wu SJ, Liu J , Chen R......... Zhang YW*, He X*, and Zhang H*. Advanced Science. 2023.09.26:10(27).

28   Zhang  YW ,  Li R ,  Li YZ........... Zhang H* and He YQ *. Signal Transduction Targeted Ther. 2023.01.07:8(1).

29   Chen T , Deng JY, Zhang YL, Liu BF .........Ma XC * and Zhang H*. The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments. Molecular Cancer. 2024.03.11:23(1). 

30   He  X , Zhang XT , Wu BL......Zhang YW & Zhang H*. The receptor binding domain of SARS-CoV-2 Omicron subvariants targets Siglec-9 to decrease its immunogenicity by preventing macrophage phagocytosis. Nature Immunology. 2024.04:25(4). 

31  Zhang YL, Chen AC, Li DY......Zhang H* & He X*. Development of T follicular helper cell-independent nanoparticle vaccines for SARS-CoV-2 or HIV-1 by targeting ICOSL. NPJ VACCINES. 2024.09.28:9(1). 

32  Xing F，Wang XM.........Zhang H*. Specific loading of oncolytic VSV on CAR enhances CAR-T cell signaling and antitumor activity. JEM.2025.9.12.222（11）.

科研项目（近三年）

1. 新型冠状病毒S蛋白与宿主细胞膜上蛋白互作机理研究和靶标鉴定，国家自然科学基金新冠专项（82041002，2020.03-2022.03）150万元，项目负责人
2. 蛋白质去泛素化参与调控抗新冠病毒体液免疫反应的机理研究，国家自然科学基金重大研究计划项目（92169201，2022.01-2025.12），290万，项目负责人
3. Development and Underlying Mechanism Study of Novel Adjuvants for SARS-CoV-2 Subunit Vaccine，国家自然科学基金外国学者研究基金项目（82150710553，2022.01-2023.12），160万，项目负责人
4. 巨噬细胞在新冠病毒感染致病及疫苗免疫过程中的调控机制研究，国自然重大研究计划项目（92369205，2024.01-2027.12），260万，项目负责人
5. 重要呼吸道病原新型纳米颗粒疫苗的研发，广州国家实验室实验室专项项目（2024.05.06-2028.10.31）, 300万，项目负责人

学术兼职

1. 国家十二五、十三五重大传染病防治/新药研发专项项目现场评委
2. 教育部长江学者评审（生命或医学一组）现场评委、创新性国家重大人才计划申请者现场评委、创业性国家重大人才计划申请者现场评委、外专千人申请者现场评委
3. 国家基金委重点项目现场评委
4. 中山大学学术委员会委员、中山大学学位评定委员会委员、中山大学教师聘任委员会委员
5. 中山大学学术委员会医科分委会副主任、中山大学学位评定委员会医科分委会委员、中山大学教师聘任委员会医科分委会委员
6. 中山医学院学术委员会主席、中山医学院学位评定委员会委员、中山医学院教师聘任委员会委员